Lexaria Bioscience Corp.

LEXX

US52886N4060

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:10:39 2024-05-28 EDT			5-day change	1st Jan Change
3.345 ^USD	+7.21%		+9.36%	+161.60%

05-21	Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	MT
05-17	Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	CI

Lexaria Bioscience Corp. Elects Ted Mckechnie as Director

June 21, 2019 at 04:21 pm

Lexaria Bioscience Corp. elected Ted Mckechnie as a director its annual and special meeting of shareholders held on June 20, 2019.

Latest news about Lexaria Bioscience Corp.

Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	05-21	MT
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	05-17	CI
Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study	05-08	CI
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	04-16	MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	04-16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-09	CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	04-02	CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	03-14	MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer	03-14	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	03-05	MT
Sector Update: Health Care	03-05	MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	03-05	MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating	03-05	MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	03-05	CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	03-04	CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study	03-04	CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	03-01	CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application	01-30	CI
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program	01-16	CI
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	01-12	CI
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream	01-11	CI
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform	01-09	CI
Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide	01-04	CI
Lexaria Bioscience Set to File Investigational New Drug Application for Hypertension Trial Within 45 Days	12-07	MT
Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update	12-07	CI

Chart Lexaria Bioscience Corp.

Duration

Period

More charts

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Companyâs patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Lexaria Bioscience Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.12 USD

Average target price

10 USD

Spread / Average Target

+220.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LEXARIA BIOSCIENCE CORP.	+164.80%	40.2M
ELI LILLY AND COMPANY	+37.62%	727B
JOHNSON & JOHNSON	-7.87%	354B
MERCK & CO., INC.	+15.57%	328B
ABBVIE INC.	-0.36%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+3.91%	164B
PFIZER, INC.	-2.14%	164B

Other Pharmaceuticals